Earnings$RVMD12:24 PM ET

Revolution Medicines Shares Rise After Phase 3 Zoldonrasib Trial Begins

By BORSA NewsroomPublished Oct 20, 2026, 12:24 PM EDTUpdated Oct 20, 2026, 12:24 PM EDT

Revolution Medicines began treating patients in a Phase 3 trial of zoldonrasib in combination with pembrolizumab and chemotherapy for first-line metastatic RAS G12D non-squamous NSCLC. Shares rose 6.8% to $194.46.

Sentimentbullish 70

Bullish · 70 of 100

Impact40

low · stays off the top drivers

Confidence80%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

Revolution Medicines began treating patients in Phase 3 RASolve 308 trial
Zoldonrasib is a G12D-selective inhibitor